Eligibility of Outpatients with Chronic Heart Failure for Sodium–Glucose Co-Transporter-2 Inhibitors

Abstract

In spite of a low number of patients actually treated with SGLT2i, we observed that a high prevalence of patients with CHF met the clinical characteristics of RCTs that have demonstrated a beneficial effect of SGLT2i.